Abstract:Chronic infection of hepatitis B virus (HBV) is still one of the public health concerns affecting human health. Although the prophylactic HBV vaccines was introduced over three decades ago, the total number of chronic hepatitis B (CHB) infection still accounts for 3.5% (257 million) of the world's population, with approximately 800000 annual deaths related to the viral infection. Currently, drugs including PEG-IFN and NAs are widely used in the treatment of HBV infection with certain degree of success. It is still difficult to achieve a high proportion of "clinical cure" with existing treatment methods. The presence of covalently closed circular DNA (cccDNA) in the infected hepatocytes is the underlying mechanism for the long-term HBV persistence and is also essential for off-therapy viral relapse. The current treatments have no or limited effects on the suppression of intrahepatic cccDNA. The availability for a reliable cccDNA quantification assay would facilitate the developmentof anti-viral drugs targeting cccDNA-targeting. In this review, we summarized the advantages and disadvantages of the existing methods for cccDNA quantitation. Specifically, the extraction method of Hirt DNA combined with Exonuclease V can effectively remove other forms of HBV DNA, and suitable for cccDNA extraction, but it needs to be further optimized. Southern blot is considered as the "gold-standard" method for cccDNA detection, but it is less sensitive and requires cumbersome procedures, making it an unlikely method for high-throughput screening used for drug development or for clinical applications. The PCR-based methods are more convenient and sensitive for cccDNA detection. However, the reliability of PCR-based method requires further optimization and validation. Different PCR-based methods were developed for quantitation of HBV cccDNA. They include selective qPCR, droplet-digital PCR, rolling circle amplification PCR, in situ PCR, invader assay, magnetic capture hybridization qPCR, etc. These PCR-based methods are widely used in clinical and laboratory research for quantitation of cccDNA. Efforts need to be made to minimize the interference from other forms of DNAs in the assays. More recently, hepatitis B core related antigen (HBcrAg)was found to be a novel marker of HBV, and its level in serum is highly correlated with intracellular cccDNA level. This biomarker, the HBcrAg level, can be used to indicate the suppression of cccDNA during different clinical antiviral therapies. The correlation needs further analysis with additional data sets. In summary, we present a review on the quantitation assays for HBV cccDNA. Such assays are important for drug developments and clinical applications for improved management of HBV infection related diseases. Performance and characteristics of various methods were compared with the areas of improvements for different assays.

Nested real-time quantitative polymerase chain reaction assay for detection of hepatitis B virus covalently closed circular DNA

[Establishment and Application of Nested Real-Time Quantitative Polymerase Chain Reaction Assay for Detection of Hepatitis B Virus Covalently Closed Circular DNA].

[A Quantitative Real Time Polymerase Chain Reaction for Detection of HBV Covalently Closed Circular DNA in Livers of the HBV Infected Patients].

Analysis of suspicious results of serum HBV DNA detected by fluorescence quantitative PCR

A New and Sensitive Method for the Quantification of HBV Cccdna by Real-Time PCR

Exonuclease I and III Improve the Detection Efficacy of Hepatitis B Virus Covalently Closed Circular DNA

A sensitive and accurate quantification method for the detection of hepatitis B virus covalently closed circular DNA by the application of a droplet digital polymerase chain reaction amplification system

Establishment and Application of a Real-Time PCR Method to Detect Hepatitis B Virus Cccdna Quantitatively

The Measurement of HBV DNA in peripheral blood mononuclear cells and its clinical applicability

Quantatitative Assays For Covalently Closed Circular Dna Of Hepatitis B Virus

Detection of HBV Covalently Closed Circular DNA

CRISPR/Cas13-assisted hepatitis B virus covalently closed circular DNA detection

The study on the rolling circle amplification for detecting hepatitis B virus covalently closed circular DNA

A quantitative method for hepatitis B virus covalently closed circular DNA enables distinguishing direct acting antivirals from cytotoxic agents

A Chromogenic In Situ Hybridization (CISH) Assay for Detection of HBV RNA, DNA, and cccDNA in Liver Tissue

Evaluation of a Novel Fully Automated Real-Time PCR Assay for Hepatitis B Virus DNA Quantification

Evaluation of reverse transcription-polymerase chain reaction and simultaneous amplification and testing for quantitative detection of serum hepatitis B virus RNA

T5 Exonuclease Hydrolysis of Hepatitis B Virus Replicative Intermediates Allows Reliable Quantification and Fast Drug Efficacy Testing of Covalently Closed Circular DNA by PCR

Quantitative Analyses of Intrahepatic HBV Cccdna and Serum HBsAg in 54 Patients with Chronic Hepatitis B

A Standardized Assay for the Quantitative Detection of Serum HBV RNA in Chronic Hepatitis B Patients.

HBV Cccdna in Patients' Sera As an Indicator for HBV Reactivation and an Early Signal of Liver Damage.